Postural Orthostatic Tachycardia Syndrome (POTS)

Condition: Postural Orthostatic Tachycardia Syndrome (POTS)  |  Category: Neurological Health  |  Reviewed by: Brian Lamkin, DO

What Is POTS?

Postural orthostatic tachycardia syndrome is a disorder of autonomic nervous system regulation characterized by an excessive heart rate increase of 30 beats per minute or more (or a heart rate exceeding 120 bpm) within 10 minutes of assuming an upright position, without a significant drop in blood pressure. The tachycardia is a compensatory response to inadequate venous return, reduced stroke volume, and impaired autonomic vasoconstriction that would normally maintain cerebral perfusion during postural changes.

POTS is not a single disease with a single mechanism. It is a clinical phenotype produced by several distinct pathophysiological processes including neuropathic autonomic damage, hyperadrenergic states, hypovolemia, mast cell degranulation, and connective tissue laxity. Identifying which mechanism is dominant in each patient is essential because the treatment approach differs fundamentally between subtypes. Managing all POTS patients with the same protocol produces inconsistent results and unnecessary symptom burden.

Why It Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

Conventional cardiology identifies the tachycardia but rarely investigates why the autonomic nervous system is dysfunctional. Functional medicine evaluates the upstream mechanisms that produce the autonomic failure.

Post-Infectious Autonomic Neuropathy

The most rapidly growing POTS subtype, particularly since COVID-19. Viral infection produces autoimmune-mediated or direct damage to small fiber autonomic nerves that regulate vascular tone and heart rate. The autonomic neuropathy impairs the normal vasoconstriction that maintains cerebral perfusion during postural changes, producing the compensatory tachycardia that defines POTS. Long COVID is now a primary risk factor for new-onset POTS.

Autoimmune Autonomic Dysfunction

Autoantibodies directed against adrenergic and muscarinic receptors have been identified in a significant subset of POTS patients. This autoimmune mechanism disrupts the normal receptor signaling that coordinates cardiovascular autonomic responses. Elevated inflammatory markers and coexisting autoimmune conditions (Hashimoto's, celiac disease, lupus) are clinical signals that autoimmunity may be driving the autonomic dysfunction.

Mast Cell Activation

Mast cell activation syndrome is present in a meaningful subset of POTS patients. Mast cell degranulation releases histamine and other vasoactive mediators that produce peripheral vasodilation, flushing, GI symptoms, and tachycardia. This creates a POTS phenotype that is responsive to mast cell stabilization and histamine blockade but unresponsive to standard beta-blocker therapy.

Deconditioning and Hypovolemia

Reduced blood volume and cardiovascular deconditioning can produce or perpetuate POTS, particularly in patients whose initial trigger led to prolonged bed rest or inactivity. Reduced plasma volume means less venous return upon standing, requiring a greater heart rate increase to maintain cardiac output. This component is addressable through graduated recumbent exercise and blood volume expansion, though it is rarely the sole driver in patients with significant POTS.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

POTS evaluation requires testing beyond the standard cardiac workup. The following markers identify the inflammatory, autoimmune, and metabolic contributors that determine treatment strategy.

How to Interpret These Labs Together

Common Patterns Seen in Patients

• "I was told it was anxiety for three years": A 26-year-old woman with tachycardia, lightheadedness upon standing, exercise intolerance, and adrenaline surges. Prescribed three different SSRIs and referred to psychiatry. An active standing test demonstrated a heart rate increase from 68 to 112 bpm within 5 minutes. POTS was confirmed objectively in the first visit.
• Post-COVID onset: A 38-year-old previously healthy runner who developed persistent tachycardia, brain fog, and exercise intolerance 4 weeks after a COVID infection. Standard cardiac workup normal. Autonomic testing confirmed POTS. Inflammatory markers elevated. Post-infectious autoimmune autonomic neuropathy was the mechanism. Anti-inflammatory and immune modulation protocol produced significant improvement over 4 months.
• POTS with concurrent mast cell activation: A patient with POTS symptoms plus flushing, abdominal cramping, and reactions to multiple medications and foods. Beta-blocker therapy produced minimal improvement. Mast cell evaluation confirmed elevated histamine and prostaglandin metabolites. Mast cell stabilization with cromolyn sodium and H1/H2 blockade produced substantial reduction in both POTS and systemic symptoms.
• The teenage girl who cannot attend school: Orthostatic intolerance producing daily lightheadedness, fatigue, and cognitive dysfunction. Attributed to school avoidance. Active standing test confirmed POTS. Ferritin 12, vitamin D 18. Iron and vitamin D repletion combined with graduated exercise reconditioning restored functional capacity within 8 weeks.

Treatment and Optimization Strategy

Subtype-Specific Intervention

Treatment effectiveness in POTS depends entirely on correctly identifying the dominant mechanism. A mast cell driven POTS requires a fundamentally different intervention than a deconditioning driven POTS, and treating both with the same beta-blocker produces suboptimal outcomes in both.

What Most Doctors Miss

• Not performing an active standing test: a 10-minute standing test with continuous heart rate monitoring can confirm POTS in the office without a tilt table. Most physicians do not perform this despite its simplicity and diagnostic power.
• Treating the tachycardia without investigating the cause: beta-blockers reduce heart rate but do not address the autonomic dysfunction, hypovolemia, mast cell activation, or autoimmunity producing the compensatory tachycardia. Heart rate control without mechanism identification is symptom suppression.
• Not evaluating for mast cell activation: the overlap between POTS and MCAS is clinically significant and frequently unrecognized. Patients with POTS plus flushing, GI reactivity, and medication sensitivity should be evaluated for concurrent MCAS.
• Dismissing the condition as anxiety: the symptom overlap between POTS and panic disorder leads to years of misdiagnosis. An active standing test objectively distinguishes autonomic dysfunction from a psychiatric condition in minutes.

When to Seek Medical Care

If you experience lightheadedness upon standing, rapid heart rate with position changes, exercise intolerance that is out of proportion to your fitness level, brain fog that improves when lying down, or unexplained fatigue with near-syncope episodes, evaluation for POTS is warranted. This is especially important if these symptoms began after a viral illness, if you have a history of joint hypermobility, or if you have been diagnosed with anxiety or panic disorder without objective cardiac or autonomic testing.

At The Lamkin Clinic, POTS evaluation includes active standing testing, autonomic assessment, inflammatory and autoimmune markers, mast cell mediators when indicated, iron and vitamin D status, thyroid panel, and cortisol evaluation to identify the specific subtype and build a mechanism-targeted treatment plan.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches POTS

At The Lamkin Clinic, POTS evaluation begins with objective autonomic testing and extends to a comprehensive inflammatory, autoimmune, and metabolic workup designed to identify the specific subtype. Treatment is built around the dominant mechanism: autoimmune modulation for autoimmune POTS, mast cell stabilization for MCAS-driven POTS, graduated reconditioning for deconditioning POTS, and combined approaches when multiple drivers are active simultaneously.

Related Conditions

Related Symptoms